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Abstract
Ductal Carcinoma In Situ (DCIS) is the most common form of breast cancer wherein its progression interrupts the hormonal
receptors and genetic variation of one’s DNA. DCIS can be caused by hereditary means, or through mutations. Fortunately, due
to the many different modes of contraction, there is a plethora of treatments available in the forms of mastectomy, radiation,
chemotherapeutic drugs, and PARP inhibitors, each with their own mechanism of action to combat the tumor and any metastatic
effects the cancer may have on the body. This paper analyzes the cancer’s mechanism of action upon the body and the positive
effects available treatments have to combat the disease.
Introduction
Breast cancer has been affecting 3.8 million women in
just the United States alone, making it the most common
cancer affecting women in said location. Breast cancer is
commonly found in both men and women with an annual
42,500 deaths for women and 2,150 for men. Presuming
a woman has not developed breast cancer before the age
of 50, the percentage of susceptibility for it jumps up by
25%, resulting that 88 out of 100,000 women can develop
ductal carcinoma in situ (DCIS) (Tomlinson-Hansen et al.
, 2021). Furthermore, genetics is also a factor as they account for 25% of breast cancer in women under age 30,
even though overall genetic mutations only account for
5-10% overall. Also, once a woman becomes post-menopausal there is a 17% increased risk of contraction every
five years (Shah ,2014). Based on these jarring statistics,
it is not surprising that the probability of a woman developing invasive breast cancer in her life is 12.3% or 1 in
every 8 women. Despite these alarming numbers, there
are a great deal of modalities to eradicate the cancer and
increase life efficacy.
Methods
This comprehensive review is based on critical analyses
of literature obtained using various databases available
through The Touro College Library online, such as PubMed
and ProQuest. The National Center for Biotechnology
(NCBI) website was also useful in providing additional
source material.
Ductal Carcinoma In Situ (DCIS)
DCIS (Ward et al., 2015), a cancer that occurs in the
mammary ducts of the breast, causing the basal myoepithelial layer of the ducts to be filled with malignant cells,
accounts for 83% of all cases of breast cancer. Normal
breast ducts lead into lobules made of small glandular
structures called acini, where there is a bilayer of cells
lining this ductal lobular system. They consist of inner luminal epithelial cells and outer luminal myoepithelial cells,
where the majority of breast lesions develop, whether benign or malignant. It is deduced that if the tumors remain
at this basement membrane, the cancer is still in situ and
not invasive (Ward, 2015).
In order to classify the intensity of cancer, five
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histological grades were established. They are compartmentalized as comedo, cribriform, micropapillary, papillary, and solid. In cribriforming DCIS, the tumor cells fill
the duct and form lumen-like projections that appear
as hollow protrusions. Micropapillary DCIS histology is
characterized by the proliferated cells projecting into the
lumen like a bunch of sticks but lack a fibrovascular core.
Papillary DCIS, unlike micropapillary DCIS, does contain
a fibrovascular core. Cribriform, micropapillary, and papillary in particular are all considered low grade lesions
and the odds of developing into an invasive carcinoma
are slim. On the other hand, tumor cells that have solid
and comedo histological features, which are cells that divide aggressively and have an abnormal appearance, have a
greater propensity to become invasive ductal carcinoma.
The spectrum of DCIS is wide with the many different
hormone receptors, mitotic pathways, and/or genetic factors that are responsible for the proliferation of the cells,
inhibition of tumor suppressor cells, and in some cases
anti-apoptotic factors. However, if DCIS is left untreated
from the moment of its inception, it would only take up
to 2.5 years for it to progress into invasive ductal carcinoma (Tomlinson-Hansen et al., 2021).
Two elements that contribute to any cancer or tumor development are the loss of the TP53 gene and p53 proteins
whose function is tumor suppression. If the DNA is not dividing properly, p53 would act against it, either by triggering
apoptosis, or activating other genes for cell repair (Sever
and Brugge, 2015), subsequently suppressing tumor development.The functionof the TP53 gene is to generate these
p53 tumor suppression proteins. Should the TP53 gene be
mutated, either through frameshift, missense, or nonsense
mutations, it would not produce proper p53 proteins, and
thus cell division would proliferate uncontrollably without
proper borders (Olivier et al., 2010).
Being that breast tissue is constantly replenishing itself,
there are hormone receptors running through it that activate cell division when hormones, namely estradiol-17β
(estrogen) and progesterone, bind to their respective
hormone receptors. The hormone of interest is then
brought inside the nucleus by the hormone-bound receptor and binds to chromatin to initiate gene transcription
and protein production. Of all DCIS cases, 75% have an ER
(estrogen receptor) dysfunction, denoted as ER+, which

Effective Treatments for Ductal Carcinoma In Situ

causes an overexpression of cell division, resulting in unregulated cancerous growth (Feng, 2018). Studies have
shown that alterations to cyclin D-1, a cell cycle regulator that stimulates the proliferation of cells, is responsible
for overexpression. In vitro experiments of breast cancer
cells have shown that an influx of estrogen in the blood
is clearly correlated with increased cyclin D-1 action or
cyclin D-1 mRNA observed in the cell (Fernandez et al.,
1998; Zwijsen et al., 1997). There comes a point where
the mutant ER will still make cyclin D-1 without there
being any estrogen there to activate its transcription
(Zwijsen et al., 1997). In fact, the overexpression of cyclin
D-1 is so ubiquitous that it is seen in 50-87% of ductal
carcinoma cases (Fernandez et al., 1998).
Accordingly, a decrease of estrogen in blood or estrogen-receptor negativity has shown an expected decrease
in cyclin D-1 activity in tumor cells. The same decrease
in cyclin D-1 has been seen when anti-estrogens were
found in the blood, further enhancing the notion that the
steroid stimulates cell proliferation. Similar is the case for
cyclin-dependent kinase inhibitors p21 and p27, whose
job is to repair DNA when the cell cycle is arrested.They
appear in abundance when anti-estrogens are counteracting the estrogen, expectantly limiting cyclin D-1 expression (Fernandez et al., 1998).
The important role of epigenetic changes such as aberrant DNA methylation and histone modification in
cancer causation, progression, and treatment has been
recognized in order to develop the proper therapeutic
response to target the transcriptional abnormalities of
the cancer. DNA methylation is commonly observed in
the binding site at the enhancers of the transcriptional
factor Erα in ER+ breast cancer, which would offer insight to the resistance of anti-estrogen chemotherapeutic
agents to the binding site (Feng et al., 2018).
Along with the estrogen receptors are progesterone
receptors in the breast that can dysregulate the cell cycle.
There are progesterone receptors on the cell surface
that allow for progesterone to interact with the cell and
to partake in the proliferation of the cell with its cell processes and mitotic division. It’s supposed to define gene
expression, mainly chromatin and genome expression,
when it binds to its steroid chemical progesterone. The
defect occurs when the cell that produces the progesterone itself is the one that receives. In other words, it goes
from paracrine signaling to autocrine signaling (Grimm,
Hartig and Edwards , 2016). This may induce migration
in early primary tumor cells and, in this way, activate
mammary stem cells, thus resulting in uncontrolled cell
division and dangerous proliferation (Feng et al., 2018).
Human epidermal growth factor receptor 2 (HER-2)

is expressed in many cases of breast cancer. HER-2 expression is regulated by transcription factor AP-2gamma
(TFAP2C). This transcription factor is one of the key regulators to hormonal responsiveness in the pathways utilized
in breast carcinoma growth. High levels of TFAP2C have
been associated with ER+ breast cancer (Wu et al. , 2020).
DNA methylation or histone modification also affect this
process of excess proliferation of cells, eventually leading to breast tumorigenesis (Feng et al., 2018). In breast
cancer specifically, HER-2 is expressed in 50% of in situ
carcinomas and eventually ends up in 20% of invasive carcinomas. It is a tyrosine kinase receptor that has an extracellular ligand-binding domain, a transmembrane domain,
and an intracellular domain. HER-2 heterodimerizes with
HER-3 since HER-3 doesn’t have any tyrosine kinase activity. Cancer is formed when the HER-2 only homo and
not heterodimerizes with HER-3. This affects many downstream signaling pathways associated with breast cancer
such as the phosphatidylinositol 4,5-bidphosphate 3-kinase
(PI3K)-AKT pathway (Albaghoush and Limaiem , 2020).
The PI3K-AKT pathway is a regulatory pathway for cell
proliferation. PI3K is activated by G protein-coupled receptors which in turn translocates protein kinase B (AKT)
to be phosphorylated by the plasma cell membrane. A
conformational change happens, allowing for two phosphorylating sites to be opened.There is a threonine that is
phosphorylated on the N-terminus and C-terminus to be
fully active. It is unknown how, but the AKT is transferred
to the plasma and nucleus where many of its substrates
are located. There is negative regulator phosphatase and
tensin homologue (PTEN) which inhibits the activation
of AKT. It reduces the amount of PI(3,4,5)P3 produced
by PI3K because the PTEN dephosphorylates the products of PI3K. Loss of PTEN either through inactivating
mutation or a lack of PTEN in circulation causes more
activation of AKT. From there the pathway enhances protein synthesis by phosphorylating mammalian target of
rapamycin or mTOR, one of the body’s protein synthesis
regulators. Activated mTOR promotes cyclin D-1 mRNA
production. Cancerous mTOR also inhibits anti-proliferative effects, so it’s not only limited to increasing output,
but also decreasing regulation as well (Osaki et al., 2004).
Whenever the cause for breast cancer is genetic alterations, it is most likely a mutation in the breast cancer
gene, most commonly known as BRCA1 and BRCA2
(BReast CAncer). The genes themselves do not induce
cancer, rather they act as tumor suppressor genes in
the DNA repair processes such as chromatin remodeling, transcription control, and cell cycle regulation. Their
tumor suppressive effects have been attributed mainly
to cell cycle checkpoints and DNA repair management.
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There are more than 1600 and 1800 known variants of
BRCA1 and BRCA2 respectively, the majority of which
induce frameshifts, leading to missense or non-functional
proteins (Lee et al. , 2020). Thus, deletion mutations and/
or loss of function in the BRCA genes lead to decreased
DNA repair efficiency and possibly give rise to the expansion of cancerous cells, elevating the risk of developing breast cancer by five to six-fold. Lifelong risk of
developing breast cancer through the BRCA1 gene is 65%
and with BRCA2 is 45%. Even though BRCA1 or BRCA2
cause 5-10% of breast cancer, 75% of all DCIS cases are
due to BRCA1 mutation (Feng et al., 2018).
Triple Negative Breast Cancer
The term triple negative breast cancer (TNBC) is due
to the fact that it is ER-, PR-, HER-2-. TNBC accounts
for 20% of all breast cancer cases and is most commonly
found in women under 40 years old. The overall consensus is that TNBCs have a frequent occurrence of multiple copy-number aberrations involving genes that lead
to alterations in multiple signal pathways, which include
the mutations/deletions of BRCA1/2 in the DNA repair
pathway (Bianchini et al. , 2016). TNBC occurs in 10-15%
of sporadic, or non-genetic caused breast cancer, but 66100% of pathogenic variant BRCA1 breast cancer. In contrast, 14-35% of TNBC cases carry BRCA2 pathogenic
variant (Lee et al. , 2020). Breast tumors arising in patients who carry BRCA1 mutations have many molecular
features of basal-like sporadic breast tumors, including a
greater likelihood of being high-grade, ER/PgR-negative,
HER2-negative, and a high frequency of TP53 mutations.
The existence of a tight association between BRCA1 mutations, basal-like breast cancer and TNBC has raised the
question as to whether BRCA1 loss of function through
other mechanisms participates in the pathogenesis of
sporadic basal-like breast cancer and TNBC; such an association could be exploited therapeutically with rational
clinical trials exploring the role of chemotherapy and
biological agents targeting defective DNA-repair pathways (Fernandez , 1998). High grade tissue is observed in
TNBCs, with aggressive division and observed necrosis.
Such a cancer would not be responsive to treatment used
for receptor-positive cancers (Feng et al., 2018). As forkhead box O (FOXO) transcription factors have a recognized role in tumor development and progression, it was
shown that FOXO3a expression was highly expressed
in TNBC tumors with negative clinical and pathological
features, including lymph node metastasis and perineural
invasion, and correlated with poor disease-free survival.
Due to the severity of TNBC, and limited treatments
available for the cancer due to its negative receptor
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status, an accurate fluorescence in situ hybridization
(FISH) assessment is taken so as to not falsely diagnose
the cancer (Bianchini et al. 2016).
Risk Factors
Women are prone to breast cancer through certain risk
factors. First off, one who has first degree relatives increases one’s risk of developing breast cancer compared
to those without a family history with a risk factor of 1.69
to 1.37, and the risk increases with the risk increases with
the number of first-degree relatives a woman has that
had or have breast cancer.
The onset of menarche also is a contributing factor to
women developing breast cancer with those whose menarche comes early having a positive-receptor cancer risk
by two-fold, while late menarche reduces the risk by 10%.
Early pregnancy has been noted to protect woman
from breast cancer. Giving birth at the age of 20, 25,and
30 can reduce the risk of breast cancer by 20%, 10%, and
5% respectively. With breastfeeding, the risk of developing breast cancer is decreased by 4.3% per one year of
breastfeeding due to the decrease in endogenous sex
hormone levels, which play a role in receptor positive
breast cancer (Shah, Rosso, & Nathanson , 2014).
Age at menopause also contributes to the increased
possibility of developing breast cancer. The delay of
menopause itself per year is a 3% increased risk and 17%
every five years (Shah, Rosso, & Nathanson , 2014). (Feng
et al., 2018)
Postmenopausal women on hormone replacement
therapy exhibit a two to four-fold increase in breast cancer (Kinsinger et al. , 2002).
There are also lifestyle risk factors that increase one’s
susceptibility to contracting breast cancer such as alcohol, inactivity, and obesity.These risks account for 21% for
all breast cancer deaths worldwide. Alcohol consumption
of 5-9.9 grams a day has been proven to increase breast
cancer risk. Physical, vigorous activity reduces risk by 5%.
If one has had cancer before, and has received radiation
therapy for treatment, the previous exposure can eventually lead to DNA mutation leading to DCIS (Shah, Rosso,
& Nathanson , 2014).
Testing
There are many tests that are performed to identify if a
woman has breast cancer. Self-feeling of something that
doesn’t belong in the breast, as well as personal observations of how the breast looks can be clear indicators
of breast cancer. Signs of breast cancer include finding a
new lump in the breast or underarm (armpit); thickening
or swelling of part of the breast; irritation or dimpling of
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breast skin.; redness or flaky skin in the nipple area or
the breast; pulling in the nipple or pain in the nipple area;
nipple discharge other than breast milk, including blood;
any change in the size or the shape of the breast, and pain
in any area of the breast. Ductal Carcinoma In Situ (DCIS)
is breast cancer that forms in the milk ducts and accounts
for 75-80% of breast cancer found in patients (Memorial
Sloan Kettering Cancer Center, 2021).
Close to 90% of breast cancer cases are found via
mammogram. The mammogram looks for microcalcifications in the breast, or what is commonly known as dense
breasts, mainly to clarify if the density in the breast is
just the crowding of cells, or rather the start of a tumor.
An MRI is also taken for equivocal findings where breast
augmentation prevents effective screening mammography.
MRI is also more specific for detecting high risk cancer
at .77-.79 as compared to mammography which is only
.33-.39 (Shah, Rosso, & Nathanson , 2014). The last test
taken is core needle biopsy, to identify which hormone
receptors the cancer is positive for, as well as if the cancer utilizes the PI3K-AKT pathway and HER-2 expression
(Tomlinson-Hansen et al., 2021).
Surgery
Effective surgery for breast cancer is a mastectomy which
is the removal of the full breast. This surgery is curative
for 98% of cases and only leaves a 1-2% recurrence rate
due to small negative margins or unseen invasive carcinomas. Breast-conserving surgery (BCS) is a surgery that
conserves the breast and only removes the cancer within and 2mm of healthy surrounding tissue for negative
margin (Tomlinson-Hansen et al. , 2021). The size of the
tumor, the location of the tumor, and the quantity of tumors determines which excision the patient will receive.
If tumor size is small, but there are many in the breast,
it would call for a mastectomy, as well as large tumors
would. A small tumor localized in one area would be a
candidate for BCS (Ward et al., 2015).
After BCS, radiation therapy will follow to eliminate
any residual disease. The NSABP B17 trial demonstrated
that in patients who underwent breast-conserving surgery and followed by radiation, there was a 50% to 60%
reduction in local recurrence with surgical excision and
radiation therapy compared to surgical excision alone
(Tomlinson-Hansen et al. , 2021). No significant difference
in survival rate has been seen down the line with BCS in
conjunction radiation therapy at 91.7% when compared
to a mastectomy at 92.8%, especially since radiation has
its downside of mutating BRCA in DNA repair to alter
its normal function (Lee et al. , 2020). The conventional
dose of radiation to the whole breast is 45-50Gy (grey)

followed by a boost to the lumpectomy bed for an additional 10-16Gy over a 6-week period. If the patient is
older than 50, hypofractionation is the preferable treatment which entails less weeks of treatment but more intense waves of radiation that target the exposure of the
radiation to normal tissue (Kim & Algan, 2021).
Radiation is significant in disease control. Although radiation therapy has its own drawbacks of possible recurrence, overall, those who had BCS in combination with
radiation have only an 8% recurrence rate as opposed to
those who had BCS without any radiation therapy whose
recurrence rate is at 18.7% (Ward et al., 2015). After 10
years, those who had radiation treatment post-operation have shown a decrease in disease by at least 50%
(Alkabban & Ferguson, 2021).
Chemotherapy for HR-positive Treatments
The general effect of chemotherapy treatment in patients
post operation has been shown to reduce the risk of recurrence by 50% (Alkabban & Ferguson, 2021). In trials of
5 years of tamoxifen therapy versus no endocrine therapy,
the recurrence rate in the tamoxifen group was approximately 50% lower than that in the control group during
the first 5 years (the treatment period) and approximately 30% lower during the next 5 years (Pan , 2017). Those
with DCIS whose status is hormone receptor positive
have a plethora of treatments available for them. Selective
estrogen receptor modulators (SERMs) act as agonists
towards estrogen receptors in the breast. Though their
structure is different than the regular steroidal structure since they have a tertiary structure, that’s enough
for them to bind to the ligand-binding domain. SERMs
include tamoxifen, toremifene, and raloxifene (Adams and
McCoy., 2010).
The use of tamoxifen is suggested for hormone positive premenopausal women due its selectivity towards
estrogen. Recommended clinical treatment is to take
tamoxifen for a 10-year period. Side effects include sexual dysfunction, irregular menstrual cycles, osteoporosis,
endometrial cancer, stroke, deep vein thrombosis and
pulmonary embolism (Tomlinson-Hansen et al. , 2021).
The outcome of utilizing aromatase inhibitors is to inhibit the cytochrome P-450 component of the aromatase
enzyme complex, which is responsible for estrogen and
progesterone biosynthesis. It prevents the conversion
of androgens into estrogen. There are two types of aromatase inhibitors: Type I and Type II. A Type I aromatase
inhibitor is exemestane, whose steroid structure is similar to the androgens and irreversibly inactivates the enzyme substrate binding site of estrogen.Type II aromatase
inhibitors are anastrozole and letrozole whose functions
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are the same as Type I, but are reversible because their
structure is not steroidal. Side effects of aromatase inhibitors are similar to those of SERMs.
Selective estrogen receptor downregulators (SERDs)
such as fulvestrant have a higher affinity for the ER than
SERMs, but do not display any agonistic activities. It is
a novel ER antagonist that binds to the ER to prevent
dimerization leading to a rapid degradation and loss of
cellular ER expression (Adams and McCoy., 2010).
Oophorectomy
Called a Prophylactic bilateral salpingo-oophorectomy,
this surgery removes the ovaries, leading to a major decrease in estrogen produced in the body. It decreases the
risks of ovarian cancer by 80% and breast cancer by 50%.
This option is mainly considered for post-menopausal
women since removal of the ovary would also remove all
hormones coming from them which includes reproductive hormones (Kim & Algan, 2021).
Hormone Receptor Negative Treatment
As discussed earlier, the PI3K-AKT pathway’s function is
to regulate HER-2 to keep control of the cell cycle so that
there isn’t too much proliferation due to the suppression
of tumor inhibitors. Trastuzumab, the first approved drug,
is a monoclonal antibody that directly targets the HER-2
protein. It reduces the risk of recurrence and death by 52%
and 33%, respectively, if combined with chemotherapy in
HER2+ early breast cancer as compared to chemotherapy
alone. The most common issue with infusion of cytotoxic chemicals in the blood is the pathway of delivery. The
chemicals are delivered through a glomerular filtration,
thus increasing the toxicity of the blood and weakening the
kidneys (Alkabban and Ferguson , 2021).
After treatment of Trastuzumab, it is necessary to follow
up with a combination of cytotoxic chemical agents that
combine for a stronger effect.These chemicals provide the
body with an ability to overcome the cancerous cells by
disturbing the cancerous cell cycle (Carlson et al., 2009)
Doxorubicin is an anthracycline derived from the streptomycin bacteria which is from the group of polyketides
(Ridley and Khosla , 2009). Anthracyclines function in
halting protein synthesis by attaching to the 16s DNA
chain of the smaller 30 chain polypeptide thus preventing
anything else from attaching and arresting cell cycle function (Waters and Tadi, 2021).
Cyclophosphamide is a type of nitrogen mustard drug
which exerts its effects through the alkylation of DNA.
The drug is not cell-cycle phase-specific and metabolizes
to an active form capable of inhibiting protein synthesis
through DNA and RNA crosslinking. The majority of the
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antineoplastic effects of cyclophosphamide are due to the
phosphoramide mustard formed from the metabolism of
the drug by liver enzymes which hydroxylate, metabolize,
and then cleave into alkylating agent phosphoramide mustard and acrolein. The phosphoramide metabolite forms
cross-linkages within and between adjacent DNA strands.
These modifications are permanent and eventually lead
to programmed cell death (Ogino and Tadi , 2021).
Fluorouracil is an antimetabolite, acting as a competitive inhibitor towards DNA synthesis. It is a homologue
that looks like the base uracil but has a fluoro group on
its fifth carbon instead of a hydrogen. This prevents the
conversion of deoxy-uridylic acid to thymidylic acid, halting DNA synthesis and cell division (National Center for
Biotechnology Information , 2022). The main issue is that
it does not differentiate between fast growing cells and
cancerous cells, therefore it will attack all fast-dividing
cells, such as hair follicles, blood cells ,mouth, stomach,
and bowel cells (Mayo Clinic, 2021).
The Taxanes Docetaxel and paclitaxel, also known as Taxol,
are mitotic inhibitors that act as a spindle poison to inhibit
microtubule dynamics and arrest the cell cycle. Docetaxel
exerts 1.2-2.6 stronger cytotoxicity than paclitaxel, and
1000 times greater than cisplatin (Katsumata , 2003).
Cisplatin is a platinum based chemotherapeutic agent
that can form bonds with the polar ends of DNA due
to platinum’s positive charge. In particular, use of cisplatin therapy has been suggested for TNBC harboring
a BRCA mutation. Cisplatin is a DNA-intercalating agent
that cross-links DNA resulting in interference with RNA
transcription and DNA replication activities. If the DNA
lesions are not repaired, DNA-damage induced cell-cycle arrest and apoptosis are triggered. Cells can become
resistant to cisplatin by several mechanisms including
change in the accumulation of the drug in cells either
by inhibited uptake or enhanced efflux, detoxification
of the drug by redox mechanisms, repair of the DNA
by excision repair mechanisms, or negative regulation of
apoptotic mechanisms. Carboplatin was developed as a
less toxic version of cisplatin, and also as a chemical with
a longer half-life, but 90% would be excreted with urine
(Hill et al., 2019).
Regarding the PI3K-AKT pathway, the initial treatment
available was Wortmannin which inhibits the PI3K-AKT
pathway thus promoting apoptosis. It was found that
the main function of Wortmannin was that it prevented the phosphorylation of the AKT protein. But, due
to its organic makeup which prevents is not soluble in
water, Wortmannin was discontinued for clinical trials.
LY294002, a water soluble Wortmannin, was developed
but its PI3K inhibitive ability was reduced. LY294002,a
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pro-apoptosis and anti-proliferative chemical reagent is
a competitive and reversible inhibitor to the ATP binding sites of PI3K, as well as suppresser of tumor growth
(Osaki et al., 2004).
One combination found to increase recovery after receiving treatment with trastuzumab is doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. Another
is docetaxel and cisplatin (Carlson et al., 2009)
TNBC Treatment
For TNBC, the cancer is not generated through any hormonal response as its name suggests, therefore, it will
require chemotherapy that will halt DNA replication.
Poly (ADP-ribose) polymerases (PARPs) attach to single
strand DNA breaks and intracellularly signals to nuclear
repair proteins to fix the DNA. In cancerous cells, PARP
reacts to repair a single stranded cell, but due to the inability of BRCA to heal double DNA strand breaks, the
cell continues to divide damaged DNA. PARP inhibitors
deactivate the PARP from reacting to the single strand
breaks which would then lead to replication fork damage,
thus causing the cell to program cell death (Lee et al. ,
2020) (Feng et al., 2018).
Other forms of treatment for TNBCs include injection of the cytotoxic chemicals as mentioned by
hormone-negative breast cancer. Surprisingly, although
TNBC has the most limited options for treatment, it has
the highest response rates to neoadjuvant chemotherapy. Approximately 30–40% of patients with early-stage
TNBC treated with standard neoadjuvant anthracycline
and taxane-based chemotherapy regimens achieve a pCR
(pathogenic complete response) after treatment (Feng
et al., 2018). A combination of a taxane and anthracyclines remain as important chemical agents needed for
treatment. Adding carboplatin to paclitaxel followed by
a dense dose of doxorubicin and cyclophosphamide has
an increased pathogenic complete response from 46-60%
due to the added cisplatin. Platinum based agents really
help in BRCA1/2 mutations with a response rate of 75%
(Feng et al., 2018).
Discussion and Conclusion
Due to the differences in the different cancer types,
concocting a treatment utilizing each chemotherapeutic
agent would not have the potency to effectively treat the
patient. On the other hand, a PARP inhibitor would be
something that all cancers whether hormone receptor
positive or negative can benefit from. Even when the
cancer is ER+ and/or PR+, the main result would still
be a halting of DNA synthesis. The only issue is whether it would be effective for hormone receptor positive

cancers. Hormone receptor positive breast cancers
would prefer tamoxifen and AIs because they directly
addresses the problem, and they will react swiftly and
target the estrogen causing the issue. There is research
that when insulin was pumped into MCF-7 breast cancer
cells followed by a cytotoxic chemotherapeutic regimen,
the pCR was higher because there was a greater absorbance of the chemicals, the cross-membrane channels
have expanded permeability due to the GLUT 1 and 3
transporters. The pathway travelled is the PI3K-AKT
pathway. Therefore, any injection of insulin can indeed
enhance responsiveness to the chemotherapy treatment
plan for whichever cancer is found while also reducing
toxicity due to glomerular filtration(Agrawal et al., 2017).
A way that usage of cytotoxic chemicals can be used even
for HR+ breast cancer is to use a taxane pre-operation
to shrink the size of the tumor before excision. This can
further reduce the need for a mastectomy and instead
one can proceed with a lumpectomy (National Cancer
Institute, 2022).
Essentially, breast cancer is something that can affect
one’s life either through hormonal avenues, specific homeostatic pathways, or genetic aberrations. Conveniently,
as many as there are variations of sickness there are as
many methods of treatment, either through surgery, radiation, chemotherapeutic drugs, cytotoxic chemicals, or
PARP inhibitors, each utilizing their own method of warfare to combat the body’s ailments. Through our analysis
of the disease and methods of treatment, we can provide
treatment to aid in safe and healthy recovery.
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